Aug. 18 at 7:29 AM
$NRXP Nothing new. The CRL was confirmed once again, quote: "completing the first-cycle FDA review of our ANDA." It is interesting that no analyst had any questions about this. If no one says when a decision can be expected - i.e. what the "shortest possible review cycle" actually is - one has to assume the worst. As a bear, I would argue that they are pumping the stock until August 19, when the lock-up period for B Group's "
$1.65 shares" ends so they can throw some at the market. Opportunity costs are high here. As a bull, I would expect the decision by the end of Q3, because that's when the NDA for NRX-100 is supposed to be filed which also depends on resolving the vial lock issue.
Geneuro sounds very positive. Also, the way JJ explained it. He really is a good storyteller (for the newbies: his novel is called "Capitol Reflections"). If one had not just started investing here yesterday, one would be hanging on his every word, but OGs know what to think of these new carrots. 😉
